Jyong Biotech Ltd. (MENS)

$10.11 -4.89 (-32.60%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,440,831
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Industry: Biotechnology
Sector: Healthcare
Phone: 886 2 2732 5205
Address:
No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan
Everythingisplanned
Everythingisplanned Apr. 2 at 7:02 PM
$MENS LFG!!
0 · Reply
Happiness77
Happiness77 Apr. 2 at 7:00 PM
$MENS Comming soon !!
0 · Reply
Everythingisplanned
Everythingisplanned Apr. 1 at 2:27 PM
$MENS Need Volume!! Lets go!!
0 · Reply
Mario19860
Mario19860 Apr. 1 at 2:03 PM
$MENS come on 35 😊
0 · Reply
Everythingisplanned
Everythingisplanned Mar. 31 at 7:57 PM
$MENS
0 · Reply
SonGoku81
SonGoku81 Mar. 30 at 11:57 PM
$MENS
0 · Reply
Everythingisplanned
Everythingisplanned Mar. 30 at 4:39 AM
$MENS https://ca.finance.yahoo.com/news/jyong-biotech-updates-potential-clinical-000000739.html
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 26 at 11:56 AM
$MENS do we think it will enter 3,00??
0 · Reply
Holymoly1269
Holymoly1269 Mar. 25 at 6:54 PM
$KALA low float AI $LABU $MENS
0 · Reply
Holymoly1269
Holymoly1269 Mar. 25 at 5:30 PM
$KALA juicy at 200million mc and 7 million float $LABU $MENS $BCRX
1 · Reply
Latest News on MENS
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Mar 27, 2026, 8:30 AM EDT - 9 days ago

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Feb 12, 2026, 8:30 AM EST - 7 weeks ago

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jan 30, 2026, 8:30 AM EST - 2 months ago

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Responds to Share Price and Volume Movement

Dec 19, 2025, 9:00 AM EST - 3 months ago

Jyong Biotech Responds to Share Price and Volume Movement

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Dec 4, 2025, 8:30 AM EST - 4 months ago

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Nov 24, 2025, 8:30 AM EST - 4 months ago

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Nov 20, 2025, 8:30 AM EST - 4 months ago

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Sep 29, 2025, 8:30 AM EDT - 6 months ago

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Sep 18, 2025, 8:30 AM EDT - 7 months ago

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Sep 16, 2025, 8:18 AM EDT - 7 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Aug 22, 2025, 9:00 AM EDT - 8 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jul 26, 2025, 8:00 AM EDT - 9 months ago

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jul 22, 2025, 10:40 AM EDT - 9 months ago

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

Jun 22, 2025, 4:20 PM EDT - 10 months ago

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

ALAB ARM CAI EGG IPO IPOS JCAP

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jun 18, 2025, 5:20 PM EDT - 10 months ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Jun 16, 2025, 11:38 PM EDT - 10 months ago

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Feb 10, 2025, 3:42 PM EST - 1 year ago

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Aug 18, 2023, 2:44 PM EDT - 2 years ago

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Aug 17, 2023, 3:16 PM EDT - 2 years ago

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Jyong Biotech IPO Registration Document (F-1)

Aug 17, 2023, 1:40 PM EDT - 2 years ago

Jyong Biotech IPO Registration Document (F-1)

Everythingisplanned
Everythingisplanned Apr. 2 at 7:02 PM
$MENS LFG!!
0 · Reply
Happiness77
Happiness77 Apr. 2 at 7:00 PM
$MENS Comming soon !!
0 · Reply
Everythingisplanned
Everythingisplanned Apr. 1 at 2:27 PM
$MENS Need Volume!! Lets go!!
0 · Reply
Mario19860
Mario19860 Apr. 1 at 2:03 PM
$MENS come on 35 😊
0 · Reply
Everythingisplanned
Everythingisplanned Mar. 31 at 7:57 PM
$MENS
0 · Reply
SonGoku81
SonGoku81 Mar. 30 at 11:57 PM
$MENS
0 · Reply
Everythingisplanned
Everythingisplanned Mar. 30 at 4:39 AM
$MENS https://ca.finance.yahoo.com/news/jyong-biotech-updates-potential-clinical-000000739.html
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 26 at 11:56 AM
$MENS do we think it will enter 3,00??
0 · Reply
Holymoly1269
Holymoly1269 Mar. 25 at 6:54 PM
$KALA low float AI $LABU $MENS
0 · Reply
Holymoly1269
Holymoly1269 Mar. 25 at 5:30 PM
$KALA juicy at 200million mc and 7 million float $LABU $MENS $BCRX
1 · Reply
Everythingisplanned
Everythingisplanned Mar. 24 at 2:34 PM
$MENS
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 24 at 2:06 PM
$MENS time to enter?
2 · Reply
brisius
brisius Mar. 23 at 3:56 PM
$MENS What's wrong?
2 · Reply
Everythingisplanned
Everythingisplanned Mar. 23 at 3:13 PM
$MENS
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 23 at 1:54 PM
$MENS Inst Trans 93.07% do we know who they are? blackrock or something else?
3 · Reply
aquira
aquira Mar. 20 at 2:53 PM
$MENS 3 weeks ago I was green now I'm 40% in the red. Fucking hell. Should i sell and just move on?
2 · Reply
Everythingisplanned
Everythingisplanned Mar. 18 at 5:50 PM
$MENS so quiet! Hopefully some news unfolds soon....
0 · Reply
aquira
aquira Mar. 16 at 4:12 PM
$MENS what the heckkkk guysssss
0 · Reply
aquira
aquira Mar. 13 at 6:37 PM
$MENS fooockeeennn shiteee man! Back to $1 land again. Fooocccckkkkkkkkkk
0 · Reply
Everythingisplanned
Everythingisplanned Mar. 11 at 7:36 PM
$MENS what just happened 🙈!
0 · Reply
Everythingisplanned
Everythingisplanned Mar. 11 at 1:49 PM
$MENS
0 · Reply
peepthestamp
peepthestamp Mar. 9 at 8:33 PM
$MENS -Aging Well 🫡
0 · Reply